Skip to main content
Publications
Weibel D, De Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J, Marsal J, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Pala E, Poblador-Plou B, Gimeno-Miguel A, Santos-Mejias A, Marconi E, Barbieri E, Stona L, Lysen T, Roy D, Hyeraci G, Girardi A, Lupattelli A, Desalegn AA, Villalobos F, Bissacco CA, Kendrick K, Garg R, Rubino H, Sturkenboom MCJM, Arana A. Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Taieb J, Fakih M, Salvatore L, Esaki T, Modest DP, Paez D, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Wang J, Tran Q, Chao J, Chen Z, Pietrantonio F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. Poster presented at the ESMO 2024 Gastrointestinal Cancers Annual Congress; June 26, 2024. Munich, Germany.
Law EH, Sherif B, Mostaghimi A, King B, Sinclair R, Mesinkovshka N, Hanson KA, Korver D, Chirila C. Patients with alopecia areata treated with ritlecitinib have improved patient-reported emotional symptoms and activity limitations due to hair loss: post hoc analyses of ALLEGRO-2b/3. Poster presented at the Maui Derm Hawaii 2024; January 22, 2024. Wailea, HI.
Spira A, Zhou X, Liao L, Yu E, Chen L, Lau A, Wang Y, Gnanasakthy A, Radford J, Hamadani M. Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2). Poster presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); September 28, 2022. Houston, TX.
Spira A, Liao L, Zhou X, Gnanasakthy A, Chen L, Ungar D, Yu E, Kilavuz T, Radford J, Hamadani M. Health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2). Poster presented at the 2022 EHA Congress; June 9, 2022. Vienna, Austria.
Spira A, Liao L, Zhou X, Sherif B, Chen L, Ungar D, Yu E, Radford J, Hamadani M. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in older versus younger patients with relapsed/refractory diffuse large b-cell lymphoma treated in a phase 2 clinical trial (LOTIS-2). Poster presented at the National Comprehensive Cancer Network (NCCN) 2022 Virtual Annual Conference; March 31, 2022.
Forsythe E, Haws RM, Argente J, Beales P, Chirila C, Clement K, Dollfus H, Martos-Moreno GA, Gnanasakthy A, Buckley BC, Mallya U, Haqq AM. Quality of life in patients with bardet-biedl syndrome in a setmelanotide phase 3 trial. Poster presented at the 2021 Obesity Week Virtual Conference; November 1, 2021.
Kuhnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clement K. Quality of life in POMC or LEPR deficiency: setmelanotide phase 3 trials. Poster presented at the 2021 Virtual Overcoming Obesity Conference; October 14, 2021.
Elimova E, Wyrwicz L, Blum SI, Xiao H, Li M, Kondo K, Davenport E, Wang J, Hunter S, Moehler MH. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): results of nivolumab plus chemotherapy (NIVO+chemo) versus chemo from CheckMate 649. Poster presented at the 2021 ASCO Quality Care Symposium; September 24, 2021.
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Can C, Chassot-Agostinho A, Reynolds M, Odom D, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the phase II GEOMETRY mono-1 study. Poster presented at the ASCO 2021 Annual Meeting; June 4, 2021.
Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 2017 ACR/ARHP Annual Meeting; November 5, 2017. San Diego, CA.
Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Porter B, Talloczy Z, Sherif B, Williams N, Keat A. Impact of alternative definitions of treatment response on long-term efficacy of secukinumab in tumour necrosis factor alpha-naïve patients with active ankylosing spondylitis. Poster presented at the British Society for Rheumatology 2017; April 25, 2017. Birmingham, United Kingdom.
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab provides better relief from psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides better relief from quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides better relief from quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab provides faster and better quality of life impact than ustekinumab in psoriasis. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 10, 2016. Las Vegas, NV.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Blauvelt A, Korman N, Mollon P, Zhou Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Vender R, Leonardi C, Puig L, Ziv M, Zhou Y, Gilloteau I, Sherif B, McLeod LD, Nyirady J, Guana A, Strober B. Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: an area under the curve analysis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Blauvelt A, Mehlis S, Vanaclocha F, Vender R, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S. Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 2016 SDPA Annual Summer Dermatology Conference; June 2016. Austin, TX. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
